Authors

Latest:

Dr Cappuzzo on Findings from the RATIONALE-315 Trial in Resectable NSCLC

Federico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.

Incyte

Latest:

The Importance of Early Recognition of and Intervention in Chronic GVHD

Andrew Spencer, MD, MBBS, FRACP, FRCPA

Latest:

Dr. Spencer on the Rationale to Evaluate Panobinostat in Multiple Myeloma

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.

Craig Kessler, MD

Latest:

Key Takeaways From Discussion

Physicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.

Leslie Randall, MD, FACOG, VCU Health

Latest:

Practical Implications for Treatment Strategies in Advanced Ovarian Cancer

Yardlee Kauffman

Latest:

Integrating New Standards for Metastatic HER2+ Breast Cancer

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Sherise Rogers, MD, MPH

Latest:

Dr Rogers on the NEO-Nal-IRI Trial in Pancreatic Adenocarcinoma

Sherise Rogers, MD, MPH, discusses the rationale for investigating irinotecan liposome injection plus 5-fluorouracil, leucovorin, and oxaliplatin in the preoperative treatment of patients with pancreatic adenocarcinoma.

Andrea Baccarelli, MD, PhD

Latest:

Dr. Baccarelli on the Effect of Environmental Factors on Cancer Diagnoses

Andrea Baccarelli, MD, PhD, discusses the effect of environmental factors on cancer diagnoses.

Dirk Schadendorf, MD, Essen University Hospital

Latest:

Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated Melanoma

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Atrayee Basu-Mallick, MD

Latest:

Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRC

Atrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Latest:

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

Chatrick Paul, SVP, Head of US Oncology Business, AstraZeneca

Latest:

Our Path Forward in Leading a Revolution in Cancer Care

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death

Gilberto Lopes, MD, University of Miami Health System

Latest:

Review of AENEAS Trial and Similar Agents

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

Sean Collins, MD, PhD

Latest:

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Hackensack Meridian John Theurer Cancer Center

Latest:

Cancer Experts at Jersey Shore University Medical Center Implanting First Targeted Liver Tumor Treatment Pumps in Patients

Jersey Shore University Medical Center is among the first hospitals in New Jersey to provide the HAI pump, which is offered at few hospitals in the country, enabling the N.J. community to stay close to home for care.

Ezra Rosen, MD, PhD

Latest:

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.